Abstract
More than half a century of research focused on ischemic brain injury mechanisms has failed to yield a widely accepted neuroprotective drug for the treatment of acute ischemic stroke (AIS). The absence of a therapeutic intervention targeted at neuroprotective mechanisms raises questions about the relevance of preclinical models in human stroke. Indeed, this failure of forward translation (traditional bench-to-bedside research) to bring candidate drugs into clinical use suggests that alternative or complementary approaches are needed. Here, we discuss the potential of reverse translational research - exploring a bedside-to-bench approach - utilizing big data genomics to discover novel AIS therapeutic targets. This approach might provide insights into new and old drug targets.
Original language | English |
---|---|
Article number | 8 |
Journal | Vessel Plus |
Volume | 5 |
DOIs | |
State | Published - 2021 |
Keywords
- Acute ischemic stroke
- Genomics
- NIH stroke scale
- Neruoprotection